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Abstract
Background: Therapy of atopic dermatitis (AD) relies on immunosuppression and/or UV irradiation. Here, we assessed
clinical efficacy and histopathological alterations induced by blue light-treatment of AD within an observational, non-
interventional study.
Methodology/Principal Findings: 36 patients with severe, chronic AD resisting long term disease control with local
corticosteroids were included. Treatment consisted of one cycle of 5 consecutive blue light-irradiations (28.9 J/cm
2).
Patients were instructed to ask for treatment upon disease exacerbation despite interval therapy with topical
corticosteroids. The majority of patients noted first improvements after 2–3 cycles. The EASI score was improved by 41%
and 54% after 3 and 6 months, respectively (p#0.005, and p#0.002). Significant improvement of pruritus, sleep and life
quality was noted especially after 6 months. Also, frequency and intensity of disease exacerbations and the usage of topical
corticosteroids was reduced. Finally, immunohistochemistry of skin biopsies obtained at baseline and after 5 and 15 days
revealed that, unlike UV light, blue light-treatment did not induce Langerhans cell or T cell depletion from skin.
Conclusions/Significance: Blue light-irradiation may represent a suitable treatment option for AD providing long term
control of disease. Future studies with larger patient cohorts within a randomized, placebo-controlled clinical trial are
required to confirm this observation.
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Introduction
Atopic dermatitis (AD) is a common inflammatory skin disease
affecting approximately 10–15% of all individuals in industrialized
countries. A genetic predisposition is well documented. The
disease severity can range from infrequent, localized skin affections
at predeliction sites to acute exacerbation of the entire skin leading
to erythrodermia requiring hospitalization. The patients suffer
from significant reductions in their quality of life due to pruritus,
sleeplessness and stigmatization [1–3].
The pathogenesis of AD is complex. Apart from genetic factors
responsible for a predisposition, several alterations of the skin
immune system (e.g. differences in the amount of anti-microbial
peptides produced by keratinocytes, alterations in the phenotype
and function of epidermal dendritic cells with the appearance of
normally absent IDEC) and stromal cells (e.g. filaggrin mutation)
are important [1]. Acute exacerbation of disease is characterized
by a dense infiltrate of the dermis with CD4
+ T cells showing a
Th2-phenotype. Under more chronic conditions, the Th2
predominance is shifted towards a Th1 immune response as
shown in atopy patch test experiments [1].
Therapy of AD is based on a regular treatment with basic
emollients supplemented with intermittent immunosuppressive
therapy of exacerbated skin disease. According to (inter)national
guidelines, immunosuppression can be achieved either locally by
application of corticosteroid- or calcineurin inhibitor-containing
ointments or systemically (e.g. using cyclosporine A, reserved
for severe AD) [2,3]. In addition, UV irradiation (especially
UVA1) has proven to be beneficial in those heavily affected
patients in whom the above mentioned interval therapy with
local immunosuppression is not sufficient for disease control.
However, UV radiation has been shown to be carcinogenic
and thus, UV phototherapy is usually not recommended as long-
term treatment, and for young and immunosuppressed patients
[2–4].
More recently, it was suggested that blue light irradiation may
represent a therapeutic alternative for long term control of AD.
Krutmann et al. showed that blue light irradiation was found to
induce a significant clinical improvement of atopic hand and foot
eczema [5]. In addition, anecdotal treatment of several patients
with severe AD was reported to be helpful for long-term control of
disease. Thus, in the present study we assessed the clinical efficacy
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of patients with severe, chronic AD.
Materials and Methods
Patients
Prior to the initiation of the present observational study, the
study protocol was approved by the local Ethics Committee of the
State Rhineland-Palatinate (Ethik Komission, Landesa ¨rztekam-
mer Rheinland-Pfalz), Germany. Between August 1
st, 2007, and
July 31
st, 2008, all adult patients ($18 years) who received full
body blue light irradiation for AD in our Department were asked
to participate in this observational, non-interventional study
(n=36). Inclusion criteria were an age $18 years, commitment
to non-smoking and the inability to provide long term control of
their AD with frequently performed interval therapy using class
II/III corticosteroids. All patients included gave written informed
consent and showed reliable compliance.
Irradiation device and treatment protocol
A photonic irradiation system (NeurodermH, Spectrometrix
Optoelectronic Systems GmbH, Berlin, Germany) was utilized. In
this newly-developed full body irradiation device, over 66% of the
resulting emission spectrum was between 400 and 500 nm (28.9 J/
cm
2) at a total fluence of 43.7 J/cm
2 (see Figure 1). A single
treatment consisted of a 24 min exposure of each side of the body.
The residual UVA emission per treatment was less than 1 J/cm
2
and the irradiation device therefore fulfilled the criteria for UV-
free radiation defined by the International Commission on Non-
Ionizing Radiation Protection of the International Radiation
Protection Agency (ICNIP/IRA).
Not before 48 hrs after the last treatment within a 5-day treatment
cycle, patients were askedtocontinuetreatmentwithlocalapplication
of topical corticosteroids, e.g. mometasone 1% cream once daily until
their eczema fully disappeared. They were instructed to then
discontinue treatment and return to our clinic to receive the next
5-day cycle of irradiation upon reappearance of their AD (flare up).
Clinical and serological information collected
On day 0 (d0), before treatment was started, clinical and
serological parameters were obtained. Similar information and
material was obtained on day 15 before the 15
th irradiation (d15),
and again after 3 and 6 months. On initiation visit, genetic
predisposition was judged using the Diepgen Score [6]. Clinical
response to treatment was assessed using the eczema area and
severity index (EASI) [7], clinical photographs of affected body
sites were taken and patients were asked questions about
additional treatments, well-being, itching, sleep, and their global
assessment of response. In addition, patients were handed the
Dermatology Life Quality Index (DLQI) [8] for completion at d0,
d15 and after 3 and 6 months.
Routine blood tests involved a differential blood count including
eosinophils (normal 0–7%), C-reactive protein (normal ,5 mg/l),
eosinophilic cationic protein (ECP, normal ,24 ng/ml), Total IgE
(normal ,100 IE/ml). ELISAs specific for human TARC (R&D),
IL-4 (ImmunoTools), IL-5 (BD), IL-10 (ImmunoTools), IFNc
Figure 1. Emission spectrum of the NeurodermH full body irradiation device.
doi:10.1371/journal.pone.0020566.g001
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serum.
Skin biopsies
Ethical approval was obtained to analyse the effects of blue light
irradiation in skin biopsies of 20 patients before, on day 5 before
the last irradiation (end of cycle 1) and on d15 before the 15
th
irradiation. Informed consent was obtained from 19 patients. Skin
biopsies were obtained in local anaesthesia from the same body
site from each individual (trunk, legs or arms). Biopsies were
generally 0.561 cm in size and were fixed in formalin. Sections
were stained with H&E to confirm the diagnosis for each patient.
Immunohistochemistry was performed using anti-CD1a (clone
M3571, dilution 1:100, Dako, Hamburg, Germany), HLA-DR
(clone LN3, 1:50), and anti-CD4 (clone 1F6, 1:40; both
Novocastra-Laboratories, Newcastle, England) to quantitate
antigen-presenting cells and T cell inflammatory responses,
respectively. Stainings were developed using the Chem Mate
detection kit from Dako, and analysed using an investigator
blinded to the patient’s identity using light microscopy.
Figure 2. Clinical improvement after blue light irradiation. A, EASI assessment of the severity of skin affection was obtained before treatment
(d0), on day 15 (d15), and after 3 and 6 months (m3 and m6, respectively). Data are presented as mean6SEM (n$29, *=p#0.05, **=p#0.005, and
***=p#0.002). B–F, Representative clinical pictures from before treatment (.1, d0) and after 6 months (.2). B+C: patient #10 – male, 38 years;
D: patient #15 – female, 41 years; E+F: patient #16 – male, 28 years.
doi:10.1371/journal.pone.0020566.g002
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Statistical comparisons were performed using Statview for
Windows and the Students t test for unpaired samples.
Results
Patient collective
Within a year, 36 adult patients with AD received full body blue
light irradiation (compare Fig. 1) within an observational, non-
interventional study. The mean age was 36.9 (62, range 20–57,
15 males/ 21 females), the diagnosis had been confirmed 26 years
ago (range 2–48), their mean Diepgen score was 21.5 (60.9, range
9–32). Due to the observational, non-interventional nature of the
study, not all patients responded to follow up requests and were
willing to donate blood for further analysis at all time points.
Clinical response
The clinical activity of AD was assessed on each visit by a
physician. As expected, we noted considerable variations in the
baseline level of AD activity. However, the study patient collective
consisted of mainly severely affected patients with an EASI [7] of
20.662.2 (range 6.8–54) (see Figure 2A). Over time, both the
percentage of body surface affected as well as the clinical
symptoms erythema, induration, excoriation and lichenification
significantly decreased as revealed by an improvement of the
EASI: At day 15, 3 and 6 months after treatment initiation, disease
severity was decreased by 29%, 41% and 54%, respectively
(n$29, p=0.06, p#0.005 and p#0.002, see Figure 2A).
In addition, on each visit, the patients were photographed to
document skin involvement. Figures 2B–F depict the clinical
response of 3 different patients. One panel (.1) shows typical AD
lesions as head/neck dermatitis, involvement of flexures and feet.
The same body sites were photographed after 6 months (panel .2).
Notably, skin maceration, erythema and scaling were markedly
reduced.
Side effects of blue light irradiation were generally mild and
consisted of local redness, warmth and itching of the skin within
the first few hours after treatment. Systemic side effects (dizziness
or head ache) were reported infrequently and disappeared within a
few hours.
Next, we assessed the frequency in which the patients received
therapy which correlates with the necessity to obtain treatment
because of a flare up. As depicted in Figure 3A, all 36 patients
asked for a minimum of 2 cycles of irradiation, although each of
them after a different time interval. 50% of the patients received at
least 5 cycles within 6 months of treatment. Interestingly, the time
interval between the last two irradiations increased in the majority
of the patients before they did not require additional treatment
cycles indirectly indicating that the flare up frequency decreased
over time.
Twenty-six of 28 (93%) and 25/28 (89%) of the patients
observed improvement of their skin and/or their itching during
treatment, respectively; 2 (skin) and 3 (itching) patients did not
benefit (see Figure 3B). The majority observed AD resolution as
well as a reduction of itching after 2–3 cycles of treatment.
Effects on quality of life
The majority of AD patients suffered from severe itching
(7.060.3 of maximal 10, mean6SEM, n=36) and sleeplessness
(5.160.5 of maximal 10, mean6SEM, n=36) (see Figure 4A+B).
In parallel to disease improvement, the degree of itching was
already reduced after 15 days of treatment (p#0.05), which
became highly significant after 3 and 6 months (,40% reduction,
see Figure 4A). In addition, the degree of sleeplessness also
decreased significantly over time (see Figure 4B).
Finally, a standardized measure for the life quality was used (see
Figure 4C) before treatment (d0), on d15 and after 3 and 6 months
[8]. The DLQI consists of 10 questions all scored between 0 (=not
relevant) to 4 (=very much affected). The DLQI total score
significantly improved during treatment (p#0.005) due to
Figure 4. Significant quality of live improvement of blue light-treatment. A+B, At the indicated time points, patients were asked to
quantify their degree of itching and sleeplessness on an analogous scale from 0=none to 10=severe. C, Prior to treatment, on day 15 and after 3 and
6 months, each patient completed the Dermatology life quality index (DLQI) consisting of 10 questions which are scored between 0=not relevant
and 4=very much affected. Data are presented as cumulative data from all 10 questions. A–C, All data are shown as mean+SEM, *=p#0.05, and
***=p#0.002 as compared to d0.
doi:10.1371/journal.pone.0020566.g004
Figure 3. Number of treatments within 6 months and time of first improvement. A, For each individual patient (n=36), the time point at
which he/she asked for a subsequent irradiation cycle due to disease exacerbation is depicted. B+C, After 6 months, all patients were asked to
indicate the irradiation cycle in which they first observed improvement of their skin and/or the itching, respectively.
doi:10.1371/journal.pone.0020566.g003
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any category. Before blue light irradiation, 48% of patients scored
the degree by which their skin condition influences their life
quality as ‘very much’ or ‘a lot’, but after 6 months of treatment,
this percentage was dropped to 21%. At this time, 33% and 46%
of the patients stated that their skin influenced their quality of life a
little or not at all, respectively.
Patient assessment
After 3 and 6 months of treatment, patients were asked to judge
about the total number, the frequency and intensity of disease
exacerbations within the last 3 months (see Figure 5A). All three
parameters improved significantly. In addition, the question ‘‘Is
the present treatment superior to previous ones?’’ was answered
with ‘yes’ in 21 cases (75% and 77%) and with ‘no’ in 7 and 6 cases
after 3 and 6 months, respectively (see Figure 5B). Seven of 27
patients observed no changes or an increase in the topical
corticosteroid use, whereas 20/27 (74%) used less or much less
local immunosuppressants (see Figure 5C). Systemic antihista-
mines were not routinely taken by all patients; consequently, 7
patients reported to use less systemic antihistamines, whereas 13
observed no change.
Serological data
Not all patients agreed to give blood upon follow-up visits (64%;
n=23/36 blood samples were analysed). Corresponding with the
clinical score, the mean total IgE was significantly elevated in our
patient collective at day 0 (7,06261,999 IE/ml). Over the
observation period of 6 months, no alteration of the IgE level
was observed (data not shown). CRP levels were not above control
levels at any point of time. Eosinophil counts were slightly elevated
as compared to controls (9.261.2%) and remained the same
throughout the observation period. Basic ECP levels were well
above normal (56627 ng/ml). Interestingly, 15 days and after 3
months after irradiation therapy initiation, increased levels of ECP
were detected of up to 78 ng/ml, which decreased to baseline by
the sixth month. We also assessed the levels of IL-4, IL-5, IL-10,
TNFa and thymus and activation regulated chemokine (TARC) in
the serum of AD patients. Serum levels of the pro- and anti-
inflammatory cytokines TNFa and IL-10 were low and no
Figure 5. Improvement of severity and frequency of disease exacerbations. A, After 3 and 6 months after blue light therapy initiation,
patients were asked about their total number of disease exacerbations within the last 3 months, and about the frequency and intensity of these flare
ups since treatment start. B, The number of patients that judged this treatment superior to prior treatments at 3 and 6 months post treatment
initiation is given.
doi:10.1371/journal.pone.0020566.g005
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TARC was elevated in our AD patient collective at day 0
(1,2866142 ng/ml), but obvious alterations over time were not
observed.
Histological findings
To assess blue light-mediated alterations in the specific skin
inflammatory infiltrate of AD patients, we obtained skin biopsies
from 19 patients on day 0, day 5 and day 15 post therapy
initiation.
First, because mast cells (MC) have been implicated in the
pathogenesis of AD, MC numbers in lesional tissue were assessed
in Giemsa-stained sections. We observed no alterations of the MC
numbers or their degranuation status upon irradiation with blue
light (data not shown).
Next, we assessed if blue light therapy resulted in alterations in
the inflammation induced by skin-infiltrating T cells (see Figure 6).
AD has been shown to be induced by (antigen-specific) CD4
+ T
cells that in the acute phase resemble Th2 cells, whereas chronic
AD is characterized by infiltrating Th1 cells. Interestingly, when
comparing the number of CD4
+ cells in skin, unlike UV-mediated
effects [8], we did not observe a decrease in the number of T cells
infiltrating the skin. In contrast, we observed a relative increase in
the number of lymphocytes. In addition, histomorphological signs
of lymphocyte apoptosis were not found in H&E stained sections
(data not shown).
Finally, antigen presenting cells (APC) were characterized using
anti-CD1a (epidermal Langerhans cells (LC), dermal DC), and
anti-HLA-DR (see Figure 6). A relative increase in the number of
CD1a
+ DC was observed for both dermal DC as well as
Langerhans cells (p=0.07). Since the staining intensity of the
LC for CD1a appeared increased as well (compare Figure 6), we
performed additional stainings for HLA-DR, expressed by APC as
well as activated T cells (see Figure 6A+B). Both dermal DC and
LC expressed more HLA-DR. Thus, in summary, unlike effects of
UV, blue light therapy did not lead to a DC depletion from skin.
Discussion
Atopic dermatitis is a common disease with high socioeconomic
impact. In the present study we assessed the efficacy and potential
mechanism of action of blue light irradiation therapy of patients
with severe, chronic AD. In line with a prior report about
treatment of atopic hand- and foot eczema [5], both the clinical
response and the patient assessments showed that full body blue
light irradiation may serve as attractive treatment alternative for
AD providing long term control of disease.
Interestingly, one of the first signs of a clinical response was a
decrease in the pruritus as reported by the patients. The overall
clinical response was determined as a ,50% improvement after 6
months as assessed by using the EASI [7]. Other important
parameters such as the frequency and intensity of disease
exacerbation, topical corticosteroid use and the total quality of
life were also improved. Interestingly, the majority of patients
observed AD resolution as well as a reduction of their pruritus
after 2–3 cycles of treatment (10–15 single irradiations), thus
decisions about a continuation of treatment can be made early.
Comparisons with regard to the effectiveness of blue light
irradiation as compared to e.g. UV-based treatment regimens are
not appropriate. However, it appears that classical first-line
treatment of acute AD with UVA1 leads to a more rapid
improvement that does not last as long [9–13]: improvement
based on reductions of the clinical response were ,30% after 1
week [10], ,67% and 40% after 3 weeks of cold-light UVA1 and
medium-dose UVA1, respectively [11], ,35% after 3 weeks of
medium-dose cold-light UVA1 [12], and ,32% and 47% after 2
and 4 weeks of bath PUVA compared to 24% and 45% after 2
and 4 weeks of UVB [13]. The improvement observed in our
patients who were selected based on their unresponsiveness to
classical interval therapy with class II-III topical corticosteroids
may thus be comparable to that of classically used UVA1
irradiation [2,3]. However, improvement of long term disease
control and not the ability to provide rapid, acute intervention for
disease exacerbation may be the main feature of blue light
therapy. The overall effectiveness of UV treatment on AD is well
accepted. However, UV is one of the main risk factors for the
development of epidermal or melanocytic skin tumors [14]. Thus,
the development of UV-free irradiations with proven therapeutic
effect is beneficial.
All patients included in the present study were suffering from
long-lasting AD with no response to standard interval treatment
using topical class II-IV corticosteroid application. Thus, blue light
treatment can be considered an ‘‘add on’’ therapy as compared to
their prior treatment protocol. However, the contribution of the
combinatory therapeutic approach to the overall efficacy of the
treatment needs to be evaluated further.
Due to the non-interventional, observational nature of the
present study, not all patients agreed to complete all questionnaires
and came to follow up assessments. Because of the study design,
patients were usually re-evaluated when they experienced a flare
up just before they received another cycle of irradiation, so the
assessments may in some cases underestimate the overall clinical
response. In addition, since treatment cycles are offered only when
disease worsening is observed, not all patients received the same
amount of irradiation. To better estimate the degree of response in
relation to established therapies such as other UV-light treatments,
clinical trials with proper control groups need to be conducted.
Using skin biopsies and serological analyses, we have started to
investigate the mechanism of action of blue light irradiation in AD.
Similar to other treatment modalities, a visible effect of this
treatment on serum parameters (i.e. total IgE, ECP, etc.) was not
obvious [2,3]. As described previously, despite the observation that
a certain Th1/Th2 ratio in the skin correlates with disease
severity, serum levels of pro- and anti-inflammatory cytokines were
low and no significant changes observed. Serum TARC was
elevated in our AD patient collective prior to the study as reported
[15], but alterations were not achieved by therapy.
The blue light-mediated alterations in the inflammatory
infiltrate of the skin involved the absence of signs of lymphocyte
or DC/LC apoptosis. Our findings are in line with a recent
Figure 6. Blue light treatment does not act though similar mechanisms as UV light irradiation. Skin biopsies of AD patients were
obtained before treatment (day 0, d0), on day 5 before irradiation and on day 15 before the last irradiation in the third cycle. Formalin-fixed skin was
sectioned and immunohistochemistry performed with anti-CD4, anti-CD1a, and anti-HLA-DR. A, The number of positive cells/mm
2 was counted in 5
representative fields per patient both in the epidermis and the dermis. Left panels indicate the mean baseline number for each individual patient
(black dots) on d0 with bars showing the mean value of all patients. White dots represent results of healthy control skin from unrelated patients.
Right panels contain cumulative data in which the percent change on d5 and d15 to baseline was calculated. Data are shown as mean6SEM (n$16,
*=p#0.05 as compared to d0). B, Representative stainings for CD4, CD1a and HLA-DR are presented for baseline day 0 and day 15 (x100
magnification for CD4 and HLA-DR, x400 for CD1a).
doi:10.1371/journal.pone.0020566.g006
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not cause DNA damage or early photo-ageing; the biological
effects observed on normal skin were transient melanogenesis and
cellular vacuolization without resulting apoptosis [16]. Thus, the
authors concluded that (short-term) utilization of visible blue light
in dermatological practice may be safe [16]. Our observations are
in stark contrast to the well known effects of UV-light on skin
inflammation, which include T cell apoptosis, and depletion of LC
from skin [9,17]. In addition, UV-induced CD4
+CD25
+ regulator
T cells (Treg) are expanded by UV-exposed cutaneous LC [18].
Both the induction of apoptotic cell death, and the induction of
Treg producing IL-10 results in UV-mediated local immunosup-
pression [9,19]. In aggregate, even though in retrospect the time
points chosen for obtaining the biopsies may not have been
optimal and futures studies should attempt to analyse skin
responses also at later time points, the effects of blue light on
skin inflammation appear to be mediated by a mechanism
different from that of UV light. With regard to the molecular
targets of blue light irradiation, oxidative stress is potentially
relevant. In addition, the degree of DNA damage and/or immune
modulatory mechanisms need to be analysed.
In summary, despite this highly selected patient collective with
high disease activity and severity, our data strongly suggest that
blue light irradiation may represent a suitable treatment option for
AD providing long term control of disease. In addition to very few
side effects, a good clinical outcome was observed together with a
high patient satisfaction. Our data together with more information
on a possible mechanism of action will have to be confirmed and
extended in a larger patient cohort within a randomized, placebo-
controlled clinical trial.
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